Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.
| Revenue (TTM) | $417.30M |
| Gross Profit (TTM) | $392.96M |
| EBITDA | $180.47M |
| Operating Margin | 46.10% |
| Return on Equity | 19.90% |
| Return on Assets | 9.04% |
| Revenue/Share (TTM) | $14.36 |
| Book Value | $43.37 |
| Price-to-Book | 6.91 |
| Price-to-Sales (TTM) | 21.15 |
| EV/Revenue | 19.19 |
| EV/EBITDA | 43.20 |
| Quarterly Earnings Growth (YoY) | 52.50% |
| Quarterly Revenue Growth (YoY) | 31.90% |
| Shares Outstanding | $29.48M |
| Float | $23.37M |
| % Insiders | 11.14% |
| % Institutions | 99.43% |
Volatility is currently contracting